Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Ara-C in Intermediate-risk AML
NCT03417427Phase 2Unknown
- Start
- Feb 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine in acute myeloid leukemia (AML). Status: unknown.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03417427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03417427.